FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180978473> ?p ?o ?g. }

• W3180978473 endingPage "1098" @default.
• W3180978473 startingPage "1093" @default.
• W3180978473 abstract "This study was to explore the efficacy and safety of camrelizumab combined with apatinib in patients with advanced liver cancer. Moreover, the relationship between peripheral blood parameters and tumor response rate was also investigated. Patients with unresectable or recurrent primary liver cancer (PLC) who received treatment from July 2019 to July 2020 in the First Affiliated Hospital of Guangxi Medical University were included in this single-center retrospective study. The patients were treated with camrelizumab (200 mg, intravenous q2w) plus apatinib (250 mg, oral qd) until the occurrence of disease progression or unbearable toxicity. All the patients underwent blood routine test and detection of lactate dehydrogenase and serum albumin levels before treatment. The primary endpoints were objective response rate (ORR) and disease control rate (DCR). This study included a total of 45 patients. The overall ORR was 33.3% [95% confidence interval (CI),19.0-47.7] and the overall DCR was 57.8% (95% CI, 42.8-72.8). The ORR and DCR were higher in the first-line treatment than those in the second-line treatment (ORR: 45.5% vs. 21.7%, DCR: 63.6% vs. 52.3%). Median progression-free survival in the second-line treatment was 10.5 months (95% CI, 7.9-13.1, P = 0.022). Adverse events occurred in 39 (86.7%) patients. Grade 3/4 adverse reactions occurred in 7 (15.6%) patients. One patient (4.3%) was terminated from treatment due to adverse events. One patient (4.3%) died, which was potentially associated with adverse events. Subgroup analysis indicated that the remission rate in patients with high lymphocyte to monocyte ratio (H-LMR) was higher than that in patients with low lymphocyte to monocyte ratio (L-LMR) (56.25% vs. 25.93%, P = 0.047), and the remission rate in patients with high Prognostic Nutritional Index (H-PNI) was higher than that in patients with low Prognostic Nutritional Index (L-PNI) (66.7% vs. 26.5%, P = 0.046). Camrelizumab combined with apatinib in the treatment of PLC showed encouraging clinical efficacy, with tolerable toxicities. Levels of PNI and LMR may serve as predictors of the prognosis of advanced PLC patients who receive immunotherapy combined with targeted therapy." @default.
• W3180978473 created "2021-07-19" @default.
• W3180978473 creator A5022434547 @default.
• W3180978473 creator A5023103876 @default.
• W3180978473 creator A5035555575 @default.
• W3180978473 creator A5041900988 @default.
• W3180978473 creator A5048662409 @default.
• W3180978473 creator A5048708798 @default.
• W3180978473 creator A5049789886 @default.
• W3180978473 creator A5054993402 @default.
• W3180978473 creator A5062896936 @default.
• W3180978473 creator A5063128754 @default.
• W3180978473 creator A5064915604 @default.
• W3180978473 creator A5068457911 @default.
• W3180978473 date "2021-07-04" @default.
• W3180978473 modified "2023-10-14" @default.
• W3180978473 title "Efficacy and biomarker exploration of camrelizumab combined with apatinib in the treatment of advanced primary liver cancer: a retrospective study" @default.
• W3180978473 cites W1973534046 @default.
• W3180978473 cites W2109218540 @default.
• W3180978473 cites W2174116386 @default.
• W3180978473 cites W2396515300 @default.
• W3180978473 cites W2534302682 @default.
• W3180978473 cites W2570334922 @default.
• W3180978473 cites W2606307526 @default.
• W3180978473 cites W2606367731 @default.
• W3180978473 cites W2889646458 @default.
• W3180978473 cites W2941271487 @default.
• W3180978473 cites W2962618676 @default.
• W3180978473 cites W2965242861 @default.
• W3180978473 cites W3008514541 @default.
• W3180978473 cites W3022919793 @default.
• W3180978473 cites W3025022288 @default.
• W3180978473 cites W3029344012 @default.
• W3180978473 cites W3029810811 @default.
• W3180978473 cites W3045915945 @default.
• W3180978473 cites W3082016849 @default.
• W3180978473 cites W3093964219 @default.
• W3180978473 cites W3119005666 @default.
• W3180978473 doi "https://doi.org/10.1097/cad.0000000000001127" @default.
• W3180978473 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34232941" @default.
• W3180978473 hasPublicationYear "2021" @default.
• W3180978473 type Work @default.
• W3180978473 sameAs 3180978473 @default.
• W3180978473 citedByCount "3" @default.
• W3180978473 countsByYear W31809784732021 @default.
• W3180978473 countsByYear W31809784732022 @default.
• W3180978473 countsByYear W31809784732023 @default.
• W3180978473 crossrefType "journal-article" @default.
• W3180978473 hasAuthorship W3180978473A5022434547 @default.
• W3180978473 hasAuthorship W3180978473A5023103876 @default.
• W3180978473 hasAuthorship W3180978473A5035555575 @default.
• W3180978473 hasAuthorship W3180978473A5041900988 @default.
• W3180978473 hasAuthorship W3180978473A5048662409 @default.
• W3180978473 hasAuthorship W3180978473A5048708798 @default.
• W3180978473 hasAuthorship W3180978473A5049789886 @default.
• W3180978473 hasAuthorship W3180978473A5054993402 @default.
• W3180978473 hasAuthorship W3180978473A5062896936 @default.
• W3180978473 hasAuthorship W3180978473A5063128754 @default.
• W3180978473 hasAuthorship W3180978473A5064915604 @default.
• W3180978473 hasAuthorship W3180978473A5068457911 @default.
• W3180978473 hasConcept C121608353 @default.
• W3180978473 hasConcept C126322002 @default.
• W3180978473 hasConcept C141071460 @default.
• W3180978473 hasConcept C167135981 @default.
• W3180978473 hasConcept C168563851 @default.
• W3180978473 hasConcept C197934379 @default.
• W3180978473 hasConcept C203092338 @default.
• W3180978473 hasConcept C207103383 @default.
• W3180978473 hasConcept C2776694085 @default.
• W3180978473 hasConcept C2780668389 @default.
• W3180978473 hasConcept C2780739268 @default.
• W3180978473 hasConcept C44249647 @default.
• W3180978473 hasConcept C71924100 @default.
• W3180978473 hasConcept C90924648 @default.
• W3180978473 hasConceptScore W3180978473C121608353 @default.
• W3180978473 hasConceptScore W3180978473C126322002 @default.
• W3180978473 hasConceptScore W3180978473C141071460 @default.
• W3180978473 hasConceptScore W3180978473C167135981 @default.
• W3180978473 hasConceptScore W3180978473C168563851 @default.
• W3180978473 hasConceptScore W3180978473C197934379 @default.
• W3180978473 hasConceptScore W3180978473C203092338 @default.
• W3180978473 hasConceptScore W3180978473C207103383 @default.
• W3180978473 hasConceptScore W3180978473C2776694085 @default.
• W3180978473 hasConceptScore W3180978473C2780668389 @default.
• W3180978473 hasConceptScore W3180978473C2780739268 @default.
• W3180978473 hasConceptScore W3180978473C44249647 @default.
• W3180978473 hasConceptScore W3180978473C71924100 @default.
• W3180978473 hasConceptScore W3180978473C90924648 @default.
• W3180978473 hasIssue "10" @default.
• W3180978473 hasLocation W31809784731 @default.
• W3180978473 hasLocation W31809784732 @default.
• W3180978473 hasOpenAccess W3180978473 @default.
• W3180978473 hasPrimaryLocation W31809784731 @default.
• W3180978473 hasRelatedWork W2166867133 @default.
• W3180978473 hasRelatedWork W2790519321 @default.
• W3180978473 hasRelatedWork W3005203090 @default.
• W3180978473 hasRelatedWork W3198736463 @default.
• W3180978473 hasRelatedWork W3201889031 @default.

• next